A Selection of Recent Papers

Secondary Structure at a Hot Spot for DNA Methylation in DNA from Human Breast Cancers. J. CLARK, S.S. SMITH (Duarte, CA, USA)


Tissue Microarrays of Human Tumor Xenografts: Characterization of Proteins Involved in Migration and Angiogenesis for Applications in the Development of Targeted Anticancer Agents. V. SMITH, G.J. WIRTH, H.-H. FIEBIG, A.M. BURGER (Freiburg, Germany; Geneva, Switzerland; Detroit, MI, USA)

Ochratoxin A Lowers mRNA Levels of Genes Encoding for Key Proteins of Liver Metabolism. C. HUNDHAUSEN, C. BOESCH-SAADATMANDI, N. MATZNER, F. LANG, R. BLANK, S. WOLFFRAM, W. BLASCHEK, G. RIMBACH (Kiel; Tübingen, Germany)

Immune Response Signatures of Benzo(a)pyrene Exposure in Normal Human Mammary Epithelial Cells in the Absence or Presence of Chlorophyllin. K. JOHN, C. KEISHA VA, D.L. RICHARDSON, A. WESTON, J. NATH (Morgantown, WV, USA)

The Protein Expression of TRP-1 and Galectin-1 in Cutaneous Malignant Melanomas. Å. BOLANDER, M. AGNARSDÓTTIR, S. STRÖMBERG, F. PONTEN, P. HESSELIUS, M. UHLEN, M. BERGQVIST (Uppsala; Stockholm, Sweden)

Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells. S.M. BOKOBZA, L. YE, H.E. KYNASTON, R.E. MANSEL, W.G. JIANG (Cardiff, UK)


Relative Quantification of Cytochrome P450 1B1 Gene Expression in Peripheral Leukocytes using LightCycler. S. HELMIG, B. HADZAAD, J. DÖHREL, J. SCHNEIDER (Giessen, Germany)

Label-free Global Serum Proteomic Profiling Reveals Novel Celecoxib-modulated Proteins in Familial Adenomatous Polyposis Patients. N. FATIMA, D. CHELIUS, B.T. LUKE, M. YI, T. ZHANG, S. STAUFFER, R. STEPHENS, P. LYNCH, K. MILLER, T. GUSZCZYNSKI, D. BORING, P. GREENWALD, I.U. ALI (Bethesda; Frederick, MD; San Jose, CA; Houston, TX, USA)


Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells. S.M. BOKOBZA, L. YE, H.E. KYNASTON, R.E. MANSEL, W.G. JIANG (Cardiff, UK)


Genomic Analysis of Prostate Cancer Stem Cells Isolated from a Highly Metastatic Cell Line. R.A. ROWEHL, H. CRAWFORD, A. DUFOUR, J. JU, G.I. BOTCHKINA (Stony Brook, NY, USA)
General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

Manuscripts and correspondence should be addressed to: Dr. J.G. Delinassios, Managing Editor, IN VIVO Editorial Office, International Institute of Anticancer Research, 1st km Kapandriotou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389. e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR website: www.iiar-anticancer.org

Selection of Recent Articles


Detection of Herpesviruses and Parvovirus B19 in Gastric and Intestinal Mucosa of Chronic Fatigue Syndrome Patients. M. FRÉMONT, K. METZGER, H. RADY, J. HULSTAERT, K. DE MEIRLEIR (Zellik; Brussels; Vilvoorde, Belgium)


Drug Resistance of Human ImmunoDeficiency Virus and its Overcoming by Natural Products, A Review. J. HUPFELD, T. EFFERTH (Heidelberg, Germany)

5-Hydroxymethylfurfural and 5-Sulfooxymethylfurfural Increases Adenoma and flat ACF Number in the Intestine of Min/+ mice. C. RØNNINGBORG, T. HUSøy, J.E. PAULSEN, J. ALEXANDER (Oslo, Norway; Nuthetal, Germany)

Distribution of [3H]corticosterone in Urine, Feces and Blood of Male Sprague-Dawley Rats after Tail Vein and Jugular Vein Injections. K.S.P. ABELSON, S.S. FARD, J. NYMAN, R. GOLDKRUHL, J. HAU (Uppsala, Sweden; Copenhagen, Denmark)

Dietary Calcium Source Influences Body Composition, Glucose Metabolism, and Hormone Levels in a Mouse Model of Postmenopausal Obesity. R.E. DE ANGEL, D. BERRIGAN, N.P. NUÑEZ, S.D. HURSTING, S.N. PERKINS (Austin; Smithville, TX; Bethesda, MD, USA)

In Vivo Studies on the Availability and Toxicity of Antisense-oligonucleotides in Bladder Cancer. C.E. BUJETZ, B. THODE, M. HAUSES, R. PRIES, A.J. MEYER, C. DOEHN, D. JOCHAM, I. KAUSCH (Lebeck; Leipzig, Germany)

Auricular Chondrocytes – From Benchwork to Clinical Applications. C. NABZDYK, J. MOLINA, E. PERIN, D. PANIAGUA, D. ROSENSTRAUCH (Berlin, Germany; Houston, TX, USA)

Effects of Neonatal Administration of Diethylstilbestrol on Aberrant Crypt Foci Induced by 7,12-Dimethylbenz[a]anthracene in Rats. H. KAWASHIMA, H. KAWAGUCHI, Y. UMÉKITA, M. SOUDA, K. GEJIMA, T. KOMOKATA, R. SAKATA, H. YOSHIDA (Ragashima, Japan)

MeSOD Genotype and Prostate Cancer Risk as a Function of NAT Genotype and Smoking Status. T. IGUCHI, S. SUGITA, C.Y. WANG, N.B. NEWMAN, T. NAKATANI, G.P. HAAS (Syracuse, NY; USA; Osaka, Japan)

Selective Anti-bacterial and Apoptosis-modulating Activities of Mastic. H. SAKAGAMI, K. KISHINO, M. KOBA YASHI, K. HASHIMOTO, A. SHIMETANI, Y. NAKAMURA, K. TAKAHASHI, T. IKARASHI, H. FURAMACHI, K. SATOH, H. NAKASHIMA, T. SHIMIZU, K. TAKEDA, S. WATANABE, W. NAKAMURA (Saitama; Fukushima; Tokyo; Kanagawa; Chiba, Japan)

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept high quality original works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy advises that priority should be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis and therapy. AR will also accept the following for publication: (a) abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) announcements of meetings related to cancer research; (c) short reviews (of approximately 1,200 words) and announcements of newly published books and journals related to cancer; and (d) announcements of awards and prizes.

The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in AR, for public archiving in PubMed Central. A main aim of AR is to ensure the prompt publication of high quality original works, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on cancer that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts in terms of grammar and style.

Format. Two types of papers may be submitted: (i) full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all the essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that of the "Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced page), including abstract, text, tables, figures and references (corresponding to 4 printed pages). Papers exceeding four (4) printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, indication of the study type "clinical", "epidemiological", or "experimental", and date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background - Materials and Methods or Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods or Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; and (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's preference. Review articles should not exceed 35 pages (approximately 250 words per double-spaced page) including all tables, figures and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, rather than photographic copies. A charge will be made for a colour plate. Figures should be numbered with Arabic numerals and include a short title, and legend if appropriate.

Tables. Each table should be submitted on a separate page, double-spaced. Tables should be numbered with Roman numerals and should include a short title, and legend if appropriate.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.


Submission of Manuscripts. You can send your article via e-mail to journals@iiar-anticancer.org, indicating in which journal you wish to be submitted (ANTICANCER RESEARCH, IN VIVO or CANCER GENOMICS & PROTEOMICS). The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments. OR You can send the manuscript of your article via regular mail in a usb stick, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address: Dr. J.G. Delinassios, International Institute of Anticancer Research (IIAR), Editorial Office of ANTICANCER RESEARCH, IN VIVO and CANCER GENOMICS & PROTEOMICS, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, GR-19014, Kapandriti, Attiki, Greece. Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent by e-mail to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each published article will be provided free-of-charge. Additional copies may be ordered after acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Claudin-1 Protein is a Major Factor Involved in the Tumorigenesis of Colorectal Cancer. Q. Huo, T. Kinugasa, L. Wang, J. Huang, J. Zhao, H. Shibaguchi, M. Kuroki, T. Tanaka, Y. Yamasita, K. Nabeshima, H. Iwasaki, M. Kuroki (Fukuoka, Japan) ................................................................. 851

* Utility and Safety of LPS-based Fermented Flour Extract as a Macrophage Activator. Y. Taniguchi, N. Yosiooka, T. Nishizawa, H. Inagawa, C. Kohchi, G.-I. Soma (Tokushima; Kagawa; Yamaguchi; Chiba, Japan) ................................................................. 859

Intracellular Localization of CD14 Protein in Intestinal Macrophages. N. Yosiooka, Y. Taniguchi, A. Yoshida, K. Nakata, T. Nishizawa, H. Inagawa, C. Kohchi, G.-I. Soma (Tokushima; Kagawa; Osaka; Yamaguchi; Chiba, Japan) ................................................................. 865

The Hedgehog Pathway is a Possible Therapeutic Target for Patients with Estrogen Receptor-negative Breast Cancer. C. Kameda, H. Tanaka, A. Yamasaki, M. Nakamura, K. Koga, N. Satoh, M. Kubo, S. Kuroki, M. Tanaka, M. Katano (Fukuoka, Japan) ................................................................. 871


Mechanism of Photofrin-enhanced Ultrasound-induced Human Glioma Cell Death. S. Hayashi, M. Yamamoto, K. Tachibana, Y. Ueno, G. Bu, T. Fukushima (Fukuoka, Japan; St. Louis, MO, USA) .... 897

* The Role of Toll-like Receptor 2 in Survival Strategies of Mycobacterium tuberculosis in Macrophage Phagosomes. A. Yoshida, H. Inagawa, C. Kohchi, T. Nishizawa, G.-I. Soma (Tokushima; Chiba; Yamaguchi; Kagawa) ................................................................. 907

Efficacy of Temozolomide Treatment in Patients with High-grade Glioma. S. Oshiro, H. Tsugu, F. Komatsu, T. Ohmura, M. Ohta, S. Sakamoto, T. Fukushima, T. Inoue (Fukuoka, Japan) ..... 911


Infliximab Treatment for Anal Fistula in Patients with Crohn’s Disease. D. Higashi, K. Futami, Y. Egawa, K. Hirano, T. Tomiyasu, Y. Ishibashi, T. Simomura, K. Nii, H. Kuroki, T. Maekawa, Y. Ono, T. Matsui (Chikushino-shi, Japan) .... 927

Flexible Structure of Cytochrome P450: Promiscuity of Ligand Binding in the CYP3A4 Heme Pocket. K. Ohkura, Y. Kawaguchi, Y. Watanabe, Y. Masubuchi, Y. Shinohara, H. Hori (Chiba; Tokushima, Japan) ................................................................. 935

Sonodynamic Therapy Consisting of Focused Ultrasound and a Photosensitizer Causes a Selective Antitumor Effect in a Rat Intracranial Glioma Model. M. Nonaka, M. Yamamoto, S. Yoshino, S.-I. Umemura, K. Sasaki, T. Fukushima (Fukuoka; Saitama, Japan) ................................................................. 943

* Reviews (pages 797, 809, 817, 823, 859, 907)